Login to Your Account


Sotagliflozen disclosin' by end of 2016

With positive top-line phase III data for its carcinoid-syndrome therapy boosting shares by 61 percent, Lexicon Pharmaceuticals Inc. was still undervalued in the view of some analysts, as Wall Street awaits late-stage data on the firm's larger opportunity: a therapy for type I diabetes, and possibly type 2. more »